<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334899/" ref="ordinalpos=3870&amp;ncbi_uid=7210846&amp;link_uid=PMC4334899" image-link="/pmc/articles/PMC4334899/figure/pone.0118168.g008/" class="imagepopup">Fig 8. Both Notch <span class="highlight" style="background-color:">signaling</span> and proteasome <span class="highlight" style="background-color:">pathway</span> contributes to the osteogenesis of hUC-MSCs..  From: The Notch <span class="highlight" style="background-color:">Signaling</span> Regulates CD105 Expression, Osteogenic Differentiation and Immunomodulation of Human Umbilical Cord Mesenchymal Stem Cells. </a></div><br /><div class="p4l_captionBody">The semi-quantitative RT-PCR shows that the treatment with 2.5 Î¼M GSI-I significantly reduces RGC32 transcription at day 1 and day 3 after osteogenic induction (A). However, whereas 5 nM Bortezomib alone reduces RGC32 transcription at day 3, not day 1, of osteogenic induction, and siNotch transfection alone slightly reduces RGC32 transcription at both day 1 and day 3, the combination of both siNotch1 transfection and Bortezomib treatment significantly reduces the transcription at both day 1 and day 3 after osteogenic induction (B).</div></div>